Regeneron , Sanofi Begin COVID-19 Clinical Program Outside Of U .
( RTTNews ) - Regeneron Pharmaceuticals Inc .
( REGN ) and Sanofi ( SNY ) have treated the first patient , outside of the U .
, in their phase 2/3 trial evaluating the rheumatoid arthritis drug Kevzara in patients hospitalized with severe COVID-19 .
This trial , initiated in Italy , Spain , Germany , France and Japan , is expected to enroll approximately 300 patients .
Earlier this month , the Companies initiated a phase 2/3 trial evaluating Kevzara in adult patients hospitalized with severe or critical COVID-19 in the U .
This study is expected to enroll 400 patients .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq , Inc .
Sign up for our newsletter to get the latest on the transformative forces shaping the global economy , delivered every Thursday .
Email Address*  Location*  Please opt-in to receive news and information about Nasdaq 's services .
If you do not opt-in you will not receive any emails from Nasdaq .
@ @ @ @ @ @ @ @ @ @ to Products , Industry News and Events .
can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy .
